Skip to main content

Table 2 Association of RBM3 IHC results and clinico-pathological features of esophageal squamous cell carcinoma samples

From: Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome

  RBM3 immunohistochemistry
  Analyzable, n Low, % High, % P value
All cancers 226 40.71 59.29  
Age group
 < 65 years 86 46.51 53.49 0.178
 > 65 years 139 37.41 62.59
Sex
 male 160 41.88 58.13 0.6362
 female 65 38.46 61.54
Tumor stage
 pT1 40 17.5 82.5 0.0061
 pT2 46 41.3 58.7
 pT3 126 46.83 53.17
 pT4 14 50 50
UICC stage
 I 55 23.64 76.36 0.0213
 II 57 45.61 54.39
 III 102 47.06 52.94
 IV 10 50 50
Tumor grading
 G1 3 33.33 66.67 0.3216
 G2 141 44.68 55.32
 G3 81 34.57 65.43
 G4 0 0 0
Resektion margin
 R0 168 39.29 60.71 0.0717
 R1 47 40.43 59.57
 R2 9 77.78 22.22
Lymph node metastasis
 N0 100 35 65 0.0192
 N1 55 32.73 67.27
 N2 40 55 45
 N3 29 58.62 41.38
Distant metastasis
 M0 216 59.72 40.28 0.366
 M1 9 44.44 55.56